Epidemic

Novanta Announces Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Wednesday, February 28, 2024
Technology, Manufacturing, Professional Services, Health, Robotics, Health Technology, Medical Devices, Other Manufacturing, Machinery, Finance, Electronic Design Automation, Acquisition, Benefit, Forecasting, Epidemic, Annual report, News, Growth, Table, Sale, Seizure, Net income, Adjustment, Pandemic, Risk, Tax rate, Climate change, Event, GAAP, Element, Medicine, Automation, Public expenditure, Tax, Security (finance), EPS, Failure, Software, Video game

In the fourth quarter of 2023, GAAP operating income was $21.7 million, compared to $26.8 million in the fourth quarter of 2022.

Key Points: 
  • In the fourth quarter of 2023, GAAP operating income was $21.7 million, compared to $26.8 million in the fourth quarter of 2022.
  • GAAP net income was $12.5 million in the fourth quarter of 2023, compared to $15.3 million in the fourth quarter of 2022.
  • GAAP diluted earnings per share (“EPS”) was $0.35 in the fourth quarter of 2023, compared to $0.42 in the fourth quarter of 2022.
  • Adjusted Diluted EPS was $0.63 in the fourth quarter of 2023, compared to $0.75 in the fourth quarter of 2022.

IQVIA Publishes its 2023 Environmental, Social and Governance Report

Retrieved on: 
Monday, February 26, 2024
Technology, Pharmaceutical, Health Technology, Environmental, Social and Governance (ESG), Health Insurance, Oncology, Artificial Intelligence, Environment, Research, Medical Devices, Infectious Diseases, Clinical Trials, Environmental Policy, Biotechnology, Professional Services, Health, Recycling, Practice Management, Managed Care, Data Analytics, Science, Climate Change, Sustainability, Data Management, RSV, Woman, Coalition, Investment, Targets, Social, Epidemic, CEPI, ESG, Annual report, Health care, Pharmacy, Patient, Science Based Targets initiative, Plastic, Survival, Lung cancer, Diagnosis, IQV, Workforce, GHG, Public, Management

IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.

Key Points: 
  • IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.
  • “We are proud that we delivered on our sustainability commitments despite the tumultuous macro-environment we have been operating in.”
    IQVIA’s full 2023 ESG report can be downloaded here .
  • We established our dedicated global public health business in 2023, which now works with more than 75 clients across the globe.
  • For the third year in a row, IQVIA was named the number one most admired company in our category, Healthcare: Pharmacy and Other Services.

Rocket Lab Successfully Returns Spacecraft Capsule to Earth, Brings Back Pharmaceuticals Made in Space

Retrieved on: 
Wednesday, February 21, 2024
Health, Communications, Satellite, Technology, General Health, Pharmaceutical, Public Relations, Investor Relations, Neutron, Multimedia, Ritonavir, Epidemic, NASA, Lab, Failure, Radio, Moon, Pandemic, Risk, Congestion, Orbit, Spacecraft, Electron, Security (finance), International Space Station, Rocket Lab, Varda Space Industries, UTTR, Environment, Transport

Rocket Lab designed, manufactured and operated a bespoke spacecraft to enable Varda’s capsule manufacturing demonstration.

Key Points: 
  • Rocket Lab designed, manufactured and operated a bespoke spacecraft to enable Varda’s capsule manufacturing demonstration.
  • The spacecraft included a full suite of Rocket Lab sub-systems and components built in-house, spanning spacecraft engine, flight software, avionics, reaction wheels, star trackers, capsule dispenser, solar panels, radio, composite structures and tanks, and more.
  • Rocket Lab also supported the mission with 24/7 satellite operations to return Varda’s capsule to Earth.
  • There can be no assurance that the future developments affecting Rocket Lab will be those that we have anticipated.

NextEra Energy and NextEra Energy Partners to meet with investors in early to mid-March

Retrieved on: 
Monday, March 4, 2024
Weather, Epidemic, Form 10-K, News, NextEra Energy, Growth, Sale, Fortune 500, Annual report, Pandemic, Health, Partner, Bureau of Land Management, Ethics, Transport, Affect, Personal injury, Electricity, Uncertainty, Professional, NEP, Environment, Pressure, Partnership, Multimedia, Natural gas, Risk, Public expenditure, NextEra Energy Partners, NEE, Insurance, Acquisition, Florida Power & Light, Terrorism, Nature, Projection, Nuclear Regulatory Commission, Policy, NextEra Energy Resources, Failure, Wind

NextEra Energy also owns a competitive clean energy business, NextEra Energy Resources, LLC, which, together with its affiliated entities, is the world's largest generator of renewable energy from the wind and sun and a world leader in battery storage.

Key Points: 
  • NextEra Energy also owns a competitive clean energy business, NextEra Energy Resources, LLC, which, together with its affiliated entities, is the world's largest generator of renewable energy from the wind and sun and a world leader in battery storage.
  • Through its subsidiaries, NextEra Energy generates clean, emissions-free electricity from seven commercial nuclear power units in Florida, New Hampshire and Wisconsin.
  • NextEra Energy Partners, LP (NYSE: NEP) is a growth-oriented limited partnership formed by NextEra Energy, Inc. (NYSE: NEE).
  • NextEra Energy Partners' strategy emphasizes acquiring, managing and owning contracted clean energy assets with stable, long-term cash flows with a focus on renewable energy projects.

NextEra Energy Capital Holdings announces offering of its Series Q junior subordinated debentures

Retrieved on: 
Tuesday, February 27, 2024
Paper, Moody's Investors Service, Prospectus, NextEra Energy Partners, Weather, Multimedia, Florida Power & Light, Ethics, NextEra Energy, Epidemic, Investment, Form 10-K, News, Transport, Growth, Terrorism, Natural gas, Sale, Nature, Fortune 500, Projection, Fitch Ratings, Annual report, Communication, Risk, Pandemic, S&P Global Ratings, Health, Interest, Nuclear Regulatory Commission, Policy, Public expenditure, Electricity, Uncertainty, NextEra Energy Resources, Insurance, Failure, Wind, Security (finance)

JUNO BEACH, Fla. , Feb. 27, 2024 /PRNewswire/ -- NextEra Energy Capital Holdings, Inc., a subsidiary of NextEra Energy, Inc. (NYSE: NEE), today announced an offering of its Series Q junior subordinated debentures due Sept. 1, 2054, (the "junior subordinated debentures") in an underwritten public offering.

Key Points: 
  • JUNO BEACH, Fla. , Feb. 27, 2024 /PRNewswire/ -- NextEra Energy Capital Holdings, Inc., a subsidiary of NextEra Energy, Inc. (NYSE: NEE), today announced an offering of its Series Q junior subordinated debentures due Sept. 1, 2054, (the "junior subordinated debentures") in an underwritten public offering.
  • NextEra Energy Capital Holdings, at its option, may redeem some or all of the junior subordinated debentures at the times and prices described in the prospectus supplement.
  • The junior subordinated debentures will be guaranteed by NextEra Energy Capital Holdings' parent company, NextEra Energy.
  • NextEra Energy expects the credit rating agencies (S&P Global Ratings, Moody's Investors Service and Fitch Ratings) to ascribe 50% equity credit to the junior subordinated debentures in the calculation of its credit metrics.

Universal Technical Institute Reports Fiscal Year 2024 First Quarter Results

Retrieved on: 
Wednesday, February 7, 2024
Security (finance), COVID-19, Growth, Table, GAAP, Failure, Disease, Regulation, Universal Technical Institute, Strategic planning, Disclosure, Public expenditure, School, Employment, Social media, Credit, Depreciation, Congress, Regulation Fair Disclosure, Acquisition, Veteran, Bank statement, Student, Epidemic, Forecasting, Bank

Management will hold a conference call to discuss the financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday, February 7, 2024, at 4:30 p.m.

Key Points: 
  • Management will hold a conference call to discuss the financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday, February 7, 2024, at 4:30 p.m.
  • A live webcast of the call will be available via the Universal Technical Institute, Inc. investor relations website at https://investor.uti.edu .
  • Please go to the website at least 10 minutes early to register, download and install any necessary audio software.
  • Alternatively, the telephone replay can be accessed through February 21, 2024, by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and entering passcode 9867059.

Monolithic Power Systems Announces Results for the Fourth Quarter and Year Ended December 31, 2023 and an Increase in Quarterly Cash Dividend

Retrieved on: 
Wednesday, February 7, 2024
Nature, Pandemic, Growth, GAAP, Research, Government, Tax, Annual report, MPS, Risk, Epidemic

The following are MPS’s financial targets for the first quarter ending March 31, 2024:

Key Points: 
  • The following are MPS’s financial targets for the first quarter ending March 31, 2024:
    Revenue in the range of $437.0 million to $457.0 million.
  • Non-GAAP gross margin (1) between 55.4% and 56.0%, which excludes an estimated 0.3% impact from stock-based compensation and related expenses.
  • Non-GAAP operating expenses (1) between $101.8 million and $103.8 million, which excludes estimated stock-based compensation and related expenses, and amortization of recently purchased intangible assets.
  • Non-GAAP operating expenses exclude the effect of stock-based compensation expense, amortization of purchased intangible assets and deferred compensation plan income (expense).

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Retrieved on: 
Wednesday, February 7, 2024
CD34, Infrared spectroscopy correlation table, COVID-19, Cell, Immune system, World Health Organization, NK, Patient, CRS, Safety, AML, Virus, Hospital, COVID, FDA, Death, CDC, MDS, Cytokine release syndrome, HSPC, Therapy, Vaccination, Master of Science, RSV, Infection, Viral, Physician, Cancer, Epidemic, Vaccine

WEXFORD, Pa., Feb. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer and infectious diseases, today announced plans to pursue DVX201, its proprietary allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment addressing various respiratory viral infections that lead to hospitalization, including the "tripledemic" of influenza, COVID-19 and respiratory syncytial virus (RSV).

Key Points: 
  • DVX201 is produced by pooling CD34+ cells isolated from multiple cord blood donations to increase lot size and immune system diversity.
  • Importantly, doses undergo stringent testing including a potency assay before treatment, to assess their ability to kill virally infected cells.
  • Additionally, DVX201 does not contain T-cells, which significantly reduces the possibility for major rejection by patients, which is a major concern for some cell therapy products.
  • DVX201, the first-ever allogeneic, cord-blood derived NK cell therapy generated from pooled donor CD34+ HSPC cells, has the potential to offer significant support to patients and to our strained healthcare system."

Western Union Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 6, 2024
Banking, Personal Finance, Professional Services, Finance, Pandemic, Growth, ESG, Digital, GAAP, Failure, Legislation, Fraud, Telephone, Government, Environment, Consumer, Intellectual property, Annual report, Terrorism, ID, Consumer Protection Act, Webcast, Risk, Epidemic, Workforce, Cryptocurrency

Additional key statistics for the quarter and historical trends can be found in the supplemental tables included with this press release.

Key Points: 
  • Additional key statistics for the quarter and historical trends can be found in the supplemental tables included with this press release.
  • As a result, the percentage changes and margins disclosed herein may not recalculate precisely using the rounded amounts provided.
  • Western Union is committed to making a positive impact.
  • For more details on how Western Union is addressing some of the most pressing issues facing society, our shared environment, and our Company, please view our latest ESG report: https://corporate.westernunion.com/esg .

Comfort Systems USA Announces Acquisition

Retrieved on: 
Friday, February 2, 2024
Building Systems, Manufacturing, HVAC, Commercial Building & Real Estate, Construction & Property, Partnership, Nature, Pandemic, Security (finance), Growth, GAAP, Failure, Intermountain West, Climate change, Safety, Tax, Wildfire, Annual report, Comfort Systems USA, Ventilation, Air conditioning, Weather, Drought, Depreciation, Disease, Flood, City, Acquisition, Comfort, Swiss cheese model, Insurance, Epidemic

Comfort Systems USA, Inc. (NYSE: FIX) (the “Company”) today announced that it has acquired J & S Mechanical Contractors, Inc. (“J & S”) headquartered in West Jordan, Utah.

Key Points: 
  • Comfort Systems USA, Inc. (NYSE: FIX) (the “Company”) today announced that it has acquired J & S Mechanical Contractors, Inc. (“J & S”) headquartered in West Jordan, Utah.
  • Brian Lane, Comfort Systems USA’s Chief Executive Officer, commented, “We are extremely happy to announce that J & S is now a part of the Comfort Systems USA family of companies.
  • We look forward to a strong partnership for our collective future.”
    Comfort Systems USA® is a leading provider of commercial, industrial, and institutional heating, ventilation, air conditioning and electrical contracting services, with 172 locations in 131 cities across the nation.
  • These forward-looking statements are based on the current expectations and beliefs of Comfort Systems USA, Inc., and its subsidiaries (collectively, the “Company”) concerning future developments and their effect on the Company.